Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse

Leukemia and Lymphoma

Volumn 55, Issue 6, 2014, Pages 1337-1344

  Jain, Preetesh ^a   Kantarjian, Hagop ^a   Patel, Keyur ^a   Faderl, Stefan ^a   Garcia Manero, Guillermo ^a   Benjamini, Ohad ^a   Borthakur, Gautam ^a   Pemmaraju, Naveen ^a   Kadia, Tapan ^a   Daver, Naval ^a   Nazha, Aziz ^a   Luthra, Raja ^a   Pierce, Sherry ^a   Cortes, Jorge ^a   Ravandi, Farhad ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

AML; Minimal residual disease; MRD; NPM1 mutations

Indexed keywords

NUCLEOPHOSMIN; NUCLEAR PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE MYELOMONOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER SURVIVAL; CYTOGENETICS; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; KARYOTYPE; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; GENETICS; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MORTALITY; MUTATION; NUCLEOTIDE SEQUENCE; PROGNOSIS; REMISSION; TREATMENT OUTCOME; TUMOR RECURRENCE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; KARYOTYPE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; NUCLEAR PROTEINS; PROGNOSIS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84901335895     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.840776     Document Type: Article

References (43)

1. Patel JP, Gonen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profi ling in acute myeloid leukemia. N Engl J Med 2012; 366: 1079-1089
2. Schlenk RF, Dohner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008; 358: 1909-1918. (Pubitemid 351620111
3. Grossmann V, Schnittger S, Kohlmann A, et al. Anovel hierarchical prognostic model of AML solely based on molecular mutations. Blood 2012; 120: 2963-2972
4. Estey EH. Acute myeloid leukemia: 2012 update on diagnosis, risk stratifi cation, and management. Am J Hematol 2012; 87: 89-99
5. Takahashi S. Current findings for recurring mutations in acute myeloid leukemia. JHematol Oncol 2011; 4: 36
6. Gianfelici V, Lahortiga I, Cools J. Chromosomal aberrations and fusion genes in myeloid malignancies. Expert Rev Hematol 2012; 5: 381-393
7. Wakita S, Yamaguchi H, Omori I, et al. Mutations of the epigenetics modifying gene (DNMT3a, TET2, IDH1/2) at diagnosis may induce FLT3-ITD at relapse in de novo acute myeloid leukemia. Leukemia 2012
8. Kronke J, Schlenk R F, Jensen K O, et al. Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: A study from the German-Austrian acute myeloid leukemia study group. JClin Oncol 2011; 29: 2709-2716
9. Falini B, Mecucci C, Tiacci E, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia wiTha normal karyotype. N Engl J Med 2005; 352: 254-266. (Pubitemid 40110814
10. Schnittger S, Schoch C, Kern W, et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia wiTha normal karyotype. Blood 2005; 106: 3733-3739. (Pubitemid 41739006
11. Thiede C, Koch S, Creutzig E, et al. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients wiThacute myeloid leukemia (AML). Blood 2006; 107: 4011-4020
12. Dohner K, Schlenk R F, Habdank M, et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults wiThacute myeloid leukemia and normal cytogenetics: Interaction wiThother gene mutations. Blood 2005; 106: 3740-3746. (Pubitemid 41739007
13. Verhaak RG, Goudswaard CS, van Putten W, et al. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): Association wiThother gene abnormalities and previously established gene expression signatures and their favorable prognostic signifi cance. Blood 2005; 106: 3747-3754. (Pubitemid 41739008
14. Shamaa S, Laimon N, Aladle DA, et al. Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients wiThcytogenetically normal acute myeloid leukemia. Hematology 2013
15. Pratcorona M, Brunet S, Nomdedeu J, et al. Favorable outcome of patients wiThacute myeloid leukemia harboring a low-Allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: Relevance to post-remission therapy. Blood 2013; 121: 2734-2738
16. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World HealThOrganization (WHO) classifi cation of myeloid neoplasms and acute leukemia: Rationale and important changes. Blood 2009; 114: 937-951
17. Falini B, Sportoletti P, Martelli MP. Acute myeloid leukemia wiThmutated NPM1: Diagnosis, prognosis and therapeutic perspectives. Curr Opin Oncol 2009; 21: 573-581
18. Falini B, Martelli MP, Bolli N, et al. Acute myeloid leukemia wiThmutated nucleophosmin (NPM1): Is it a distinct entity? Blood 2011; 117: 1109-1120
19. Papadaki C, Dufour A, Seibl M, et al. Monitoring minimal residual disease in acute myeloid leukaemia wiThNPM1 mutations by quantitative PCR: Clonal evolution is a limiting factor. Br J Haematol 2009; 144: 517-523
20. Suzuki T, Kiyoi H, Ozeki K, et al. Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia. Blood 2005; 106: 2854-2861. (Pubitemid 41510764
21. Kuzmanovic M, Tosic N, Colovic N, et al. Prognostic Impact of NPM1 Mutations in Serbian Adult Patients wiThAcute Myeloid Leukemia. Acta Haematol 2012; 128: 203-212
22. Boissel N, Renneville A, Biggio V, et al. Prevalence, clinical profi le, and prognosis of NPM mutations in AML wiThnormal karyotype. Blood 2005; 106: 3618-3620. (Pubitemid 41609201
23. Colombo E, Alcalay M, Pelicci PG. Nucleophosmin and its complex network: A possible therapeutic target in hematological diseases. Oncogene 2011; 30: 2595-2609
24. Borer RA, Lehner CF, Eppenberger HM, Nigg EA. Major nucleolar proteins shuttle between nucleus and cytoplasm. Cell 1989; 56: 379-390
25. Federici L, Falini B. Nucleophosmin mutations in acute myeloid leukemia: A tale of protein unfolding and mislocalization. Protein Sci 2013
26. Colombo E, Marine JC, Danovi D, Falini B, Pelicci PG. Nucleophosmin regulates the stability and transcriptional activity of p53. Nat Cell Biol 2002; 4: 529-533. (Pubitemid 34752440
27. Bertwistle D, Sugimoto M, Sherr CJ. Physical and functional interactions of the Arf tumor suppressor protein wiThnucleophosmin/ B23. Mol Cell Biol. 2004; 24: 985-996. (Pubitemid 38112164
28. Konoplev S, Huang X, Drabkin HA, et al. Cytoplasmic localization of nucleophosmin in bone marrow blasts of acute myeloid leukemia patients is not completely concordant wiThNPM1 mutation and is not predictive of prognosis. Cancer 2009; 115: 4737-4744
29. Greiner J, Ono Y, Hofmann S, et al. Mutated regions of nucleophosmin 1 elicit boThCD4 (-) and CD8 (-) T-cell responses in patients wiThacute myeloid leukemia. Blood 2012; 120: 1282-1289
30. Grimwade L, Gudgin E, Bloxham D, et al. Detection of cytoplasmic nucleophosmin expression by imaging fl ow cytometry. Cytometry A 2012; 81: 896-900
31. Thol F, Kolking B, Damm F, et al. Next-generation sequencing for minimal residual disease monitoring in acute myeloid leukemia patients wiThFLT3-ITD or NPM1 mutations. Genes Chromosomes Cancer 2012; 51: 689-695
32. Schnittger S, Kern W, Tschulik C, et al. Minimal residual disease levels assessed by NPM1 mutation-specifi c RQ-PCR provide important prognostic information in AML. Blood 2009; 114: 2220-2231
33. Ommen HB, Schnittger S, Jovanovic JV, et al. Strikingly diff erent molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias. Blood 2010; 115: 198-205
34. Kristensen T, Moller MB, Friis L, Bergmann OJ, Preiss B. NPM1 mutation is a stable marker for minimal residual disease monitoring in acute myeloid leukaemia patients wiThincreased sensitivity compared to WT1 expression. Eur J Haematol 2011; 87: 400-408
35. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003; 21: 4642-4649. (Pubitemid 46594039
36. Ravandi F, Jorgensen JL. Monitoring minimal residual disease in acute myeloid leukemia: Ready for prime time? J Natl Compr Canc Netw 2012; 10: 1029-1036
37. Buccisano F, Maurillo L, Del Principe MI, et al. Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. Blood 2012; 119: 332-341
38. Palmisano M, Grafone T, Ottaviani E, Testoni N, Baccarani M, Martinelli G. NPM1 mutations are more stable than FLT3 mutations during the course of disease in patients wiThacute myeloid leukemia. Haematologica 2007; 92: 1268-1269. (Pubitemid 350144192
39. Bacher U, Haferlach C, Kern W, Haferlach T, Schnittger S. Prognostic relevance of FLT3-TKD mutations in AML: The combination matters-An analysis of 3082 patients. Blood 2008; 111: 2527-2537
40. Boonthimat C, Thongnoppakhun W, Auewarakul CU. Nucleophosmin mutation in Southeast Asian acute myeloid leukemia: Eight novel variants, FLT3 coexistence and prognostic impact of NPM1/ FLT3 mutations. Haematologica 2008; 93: 1565-1569
41. Chou WC, Tang JL, Lin LI, et al. Nucleophosmin mutations in de novo acute myeloid leukemia: The age-Dependent incidences and the stability during disease evolution. Cancer Res 2006; 66: 3310-3316
42. Schneider F, Hoster E, Schneider S, et al. Age-Dependent frequencies of NPM1 mutations and FLT3-ITD in patients wiThnormal karyotype AML (NK-AML). Ann Hematol 2012; 91: 9-18
43. Becker H, Marcucci G, Maharry K, et al. Favorable prognostic impact of NPM1 mutations in older patients wiThcytogenetically normal de novo acute myeloid leukemia and associated gene-And microRNA-expression signatures: A Cancer and Leukemia Group B study. JClin Oncol 2010; 28: 596-604